ArticleBMC neurology2025
Switching from alteplase to tenecteplase for stroke thrombolysis: short-term effects on treatment metrics and early functional outcomes.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imaging patterns of hemorrhagic transformation after tenecteplase versus alteplase in real-world practice.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBesides its more advantageous pharmacological profile compared to alteplase (rt-PA), increasing evidence suggest a favorable clinical efficacy and safety of tenecteplase (TNK) as alternative thrombolytic agent for the treatment of acute ischemic stroke (AIS). We aimed to analyze the short-term effects of the switch in thrombolytics at our tertiary care stroke center.
methodsWe performed a retrospective analysis of patients receiving intravenous thrombolysis (IVT) for AIS in the time window < 4.5 h, including patients treated with rt-PA (from January 1st to June 30, 2024) and patients treated with TNK (from July 1st to December 31, 2024). Primary and secondary endpoints were the workflow times and the modified Rankin Scale (mRS) at discharge as the early functional outcome. Safety outcomes included any intracerebral hemorrhage (ICH) on follow-up imaging at 24 h, symptomatic (s)ICH and death by day 7.
resultsDuring the period of 12 months, n = 139 patients received IVT in the 4.5 h time window. Median door to needle (DTN) times were significantly shorter for patients treated with TNK (n = 74) compared to rt-PA (n = 65) (TNK 23 min [IQR 32–17] vs. rt-PA 28 min [IQR 33–22], p = 0.047). Patients undergoing endovascular thrombectomy (EVT) after TNK treatment had significantly shorter door to groin (DTG) times in comparison to treatment with rt-PA prior to EVT (p = 0.002). No significant differences between the groups were found for early functional outcome (p = 0.194 for patients with, p = 0.852 for patients without EVT), the rate of sICH (TNK vs. rt-PA: 17.6 vs. 4.2%, p = 0.290 with EVT and 3.6 vs. 0%, p = 0.507 without EVT) and mortality (TNK vs. rt-PA: 17.6 vs. 4.2%, p = 0.290 with EVT and 7.0 vs. 2.4%, p = 0.393 without EVT).
conclusionsTransition from rt-PA to TNK for AIS treatment < 4.5 h after onset at a tertiary care center seems feasible and resulted in shorter onset to treatment durations. Functional outcomes at discharge were comparable between the groups. Rates of ICH, sICH and mortality were numerically higher in the TNK group. Further data are required to assess the clinical efficacy and safety of TNK after the transition from rt-PA in real-world scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.